Hydreight Technologies Inc (TSE:NURS) has released an update.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Hydreight Technologies Inc. expands its medical service offerings by providing access to Tirzepatide, an innovative medication for type 2 diabetes and weight loss, through its extensive network of over 3,000 nurses across the United States. This addition complements their existing GLP-1 medication options and taps into the growing weight-loss drug market, which is projected to reach $100 billion by 2030. Tirzepatide, known for its dual-action and efficacy, is now available at more than 100 white-label locations nationwide.
For further insights into TSE:NURS stock, check out TipRanks’ Stock Analysis page.